中国P站

Epigenetics; Obesity; Metabolic disorders; Deoxyribonucleic Acid methylation; Histone modifications; MicroRNAs; Gene expression; Adipose tissue; Therapeutic interventions; Genetics

Introduction

The complex interplay of genetic and environmental factors significantly drives the global health challenge of obesity and its associated metabolic disorders. Recent research has profoundly elucidated the critical role of epigenetic mechanisms in this pathogenesis. These mechanisms, including Deoxyribonucleic Acid (DNA) methylation, histone modifications, and non-coding Ribonucleic Acids (RNAs), regulate gene expression, thereby influencing metabolic health. Specifically, a review highlights how these epigenetic modifications are shaped by environmental factors and diet, impacting gene expression within key metabolic tissues, and suggesting new avenues for therapeutic interventions[1].

Expanding on this, a comprehensive overview of the epigenetic landscape in obesity discusses how DNA methylation, histone modifications, and microRNAs mediate the effects of both genetic predispositions and environmental influences on metabolism. This perspective emphasizes the considerable potential for epigenetic interventions in both preventing and treating obesity and its complications, underscoring the necessity for further exploration into targeted therapies[2].

Building on these foundational understandings, another review systematically integrates current knowledge on both genetic predispositions and epigenetic mechanisms in obesity. This work clarifies how gene-environment interactions, mediated by these precise epigenetic changes, significantly contribute to weight gain and associated comorbidities, revealing the intricate nature of obesity pathogenesis and identifying potential targets for personalized medicine strategies[3].

Further investigations delve into the specific roles of epigenetic modifications like DNA methylation, histone acetylation, and microRNAs in the development of obesity and its metabolic complications. It becomes clear these mechanisms are highly sensitive to lifestyle and dietary factors, offering valuable insights into possible therapeutic targets for either preventing or reversing adverse metabolic outcomes[4].

While epigenetics plays a crucial part, the genetic underpinnings of obesity remain a significant area of study. Research focuses on monogenic, syndromic, and polygenic forms, identifying various susceptibility genes and explaining their functional roles. This genetic knowledge is vital for informing personalized nutrition and precision medicine approaches aimed at obesity prevention and management[5].

Beyond general mechanisms, specific epigenetic regulations impact adipose tissue directly. One article explores how DNA methylation, histone modifications, and non-coding RNAs contribute to adipose tissue dysfunction in obesity. It elucidates how these changes impair adipocyte development, reduce fat storage capacity, and disrupt hormone secretion, which ultimately exacerbates metabolic complications[6].

This perspective is complemented by another review outlining the significant role of epigenetic modifications in the etiology and progression of obesity and related metabolic diseases. It explains how diet, lifestyle, and environmental factors induce epigenetic changes that alter gene expression, thereby suggesting that targeting these reversible modifications could be a promising strategy for therapeutic interventions[7].

The impact extends intergenerationally, as investigations reveal how maternal obesity leads to epigenetic alterations in offspring, increasing their susceptibility to obesity and metabolic disorders. This research underscores the critical role of maternal diet and environment during pregnancy in programming the offspring's metabolic health through DNA methylation and histone modifications[8].

Moreover, the intricate epigenetic mechanisms governing adipogenesis, which is fat cell development, and the maintenance of metabolic homeostasis are key. Studies discuss how DNA methylation, histone modifications, and non-coding RNAs regulate gene expression pathways crucial for adipose tissue function, offering further insights into therapeutic targets for various metabolic disorders[9].

MicroRNAs, in particular, stand out as pivotal epigenetic regulators in the pathogenesis of obesity and metabolic syndrome. Various microRNAs are shown to influence adipogenesis, insulin sensitivity, and energy metabolism, presenting them as promising biomarkers and therapeutic targets[10].

This collective body of work highlights the dynamic and multifaceted nature of obesity and metabolic disease, underscoring the potential of epigenetic research to uncover new preventative and treatment strategies.

Description

The pathogenesis of obesity and associated metabolic disorders is a complex landscape shaped by both genetic predispositions and environmental influences. Epigenetic mechanisms are emerging as crucial mediators in this dynamic interaction, offering reversible targets for intervention. Research indicates that various epigenetic modifications, including Deoxyribonucleic Acid (DNA) methylation, histone modifications, and non-coding Ribonucleic Acids (RNAs), are central to the development and progression of obesity[1]. These modifications are highly responsive to external factors such as diet and overall environmental conditions, directly impacting gene expression in key metabolic tissues. Understanding these fundamental mechanisms provides a robust framework for developing innovative therapeutic strategies[1]. The epigenetic landscape of obesity, comprehensively reviewed, underscores how DNA methylation, histone modifications, and microRNAs serve as pivotal links between genetic backgrounds, environmental exposures, and metabolic outcomes[2]. This insight strongly suggests that epigenetic interventions could be a powerful tool in the prevention and treatment of obesity and its related complications, prompting further dedicated research into targeted therapies[2].

A deeper look reveals that epigenetic changes are not merely contributors but active participants in shaping metabolic health. One systematic review combines current understanding of genetic predispositions and epigenetic mechanisms, illustrating how gene-environment interactions, primarily mediated by epigenetic alterations, drive weight gain and associated comorbidities[3]. This perspective emphasizes the profound complexity of obesity pathogenesis and identifies promising avenues for personalized medicine approaches. Similarly, studies have meticulously detailed the role of specific epigenetic modifications, such as DNA methylation, histone acetylation, and microRNAs, in the intricate pathogenesis of obesity and its metabolic complications[4]. It is notable that these mechanisms are significantly influenced by lifestyle choices and dietary patterns, which offers critical insights into potential therapeutic targets aimed at preventing or reversing adverse metabolic outcomes[4]. These findings collectively highlight that the interplay of intrinsic genetic factors and extrinsic environmental cues dictates metabolic fate through epigenetic programming.

While epigenetic regulation offers a dynamic layer of control, the foundational genetic determinants of obesity cannot be overlooked. Comprehensive reviews cover monogenic, syndromic, and polygenic forms of obesity, identifying numerous susceptibility genes and elucidating their functional roles[5]. This genetic knowledge is indispensable for advancing personalized nutrition and precision medicine, providing tailored strategies for obesity prevention and management[5]. When considering specific tissue impacts, the epigenetic regulation of adipose tissue dysfunction in obesity stands out as a critical area. This research explores how DNA methylation, histone modifications, and non-coding RNAs contribute to impaired adipocyte development, diminished fat storage capacity, and disrupted hormone secretion[6]. These dysfunctions ultimately exacerbate metabolic complications, painting a clear picture of how epigenetic changes contribute to cellular and tissue-level problems[6].

The broader impact of epigenetics on obesity-related diseases, from underlying mechanisms to potential therapeutic strategies, forms another significant area of study[7]. It is understood that diet, lifestyle, and environmental factors consistently induce epigenetic changes that consequently alter gene expression. This reversibility of epigenetic modifications presents an exciting and promising strategy for future therapeutic interventions[7]. Moreover, the influence of epigenetics extends across generations. Research on maternal obesity highlights how epigenetic alterations in offspring increase their susceptibility to obesity and metabolic disorders[8]. This critical work emphasizes the profound role of maternal diet and environment during pregnancy in programming offspring's metabolic health through specific modifications like DNA methylation and histone modifications, demonstrating long-lasting impacts[8].

Finally, understanding the intricate epigenetic mechanisms governing adipogenesis, the process of fat cell development, and the maintenance of metabolic homeostasis is vital. Studies explain how DNA methylation, histone modifications, and non-coding RNAs precisely regulate gene expression pathways essential for proper adipose tissue function[9]. These insights are crucial for identifying novel therapeutic targets for various metabolic disorders[9]. Specifically, microRNAs (miRNAs) have been identified as key epigenetic regulators in the pathogenesis of obesity and metabolic syndrome[10]. These diverse microRNAs exert influence over adipogenesis, insulin sensitivity, and energy metabolism, thus positioning them as promising biomarkers and therapeutic targets for diagnosis and treatment[10]. The holistic view from these studies underscores the profound influence of epigenetic regulation in all facets of obesity, from its origins and progression to its potential treatment.

Conclusion

Current research extensively explores the genetic and epigenetic underpinnings of obesity and related metabolic disorders, recognizing them as complex multifactorial conditions. Epigenetic mechanisms, primarily Deoxyribonucleic Acid (DNA) methylation, histone modifications, and non-coding Ribonucleic Acids (RNAs) such as microRNAs, play a crucial role in regulating gene expression within key metabolic tissues. These modifications are significantly influenced by external factors like environmental exposures, diet, and lifestyle choices, effectively bridging the gap between an individual's genetic predispositions and the actual manifestation of disease. Studies highlight how these epigenetic changes specifically contribute to adipose tissue dysfunction, impairing normal fat cell development, diminishing storage capacity, and disrupting essential hormone secretion, thereby exacerbating metabolic complications and progression. The field also deeply examines the intricate interplay of genetics and epigenetics, clarifying how dynamic gene-environment interactions, mediated by these reversible epigenetic changes, contribute directly to pathological weight gain and associated comorbidities. Specific attention is given to the critical impact of maternal obesity, showing how epigenetic alterations during pregnancy can program offspring for an increased susceptibility to obesity and metabolic disorders later in life. Furthermore, the role of microRNAs is emphasized as key epigenetic regulators that profoundly influence adipogenesis, insulin sensitivity, and overall energy metabolism, positioning them as promising biomarkers for diagnosis and novel therapeutic targets. Collectively, this comprehensive body of work consistently underscores the considerable potential for epigenetic interventions in both preventing and treating obesity, strongly suggesting that therapeutically targeting these reversible modifications offers new and promising avenues for personalized medicine and effective treatment strategies.

References

1. Li Q, Wenjing M, Dong L (2023) .J Med Genet 60:685-695.

   , ,

2. Charlotte L, Rohit NK, Tove R (2021) .Cell Metab 33:879-889.

   , ,

3. Shuping M, Xiaoting L, Xiaochen W (2022) .Obes Facts 15:352-368.

   , ,

4. Claudia PG, Myriam GS, Jose CG (2023) .Int J Mol Sci 24:8236.

   , ,

5. Ioannis K, Alkmini K, Katerina S (2022) .Nutrients 14:2838.

   , ,

6. Yan H, Xiaoting P, Qun C (2022) .Front Endocrinol (Lausanne) 13:951566.

   , ,

7. Jian D, Wei D, Zhen L (2023) .Front Genet 14:1119561.

   , ,

8. Yuan C, Dan Y, Ying W (2021) .Front Genet 12:713292.

   , ,

9. Xuan S, Xiaoyu Z, Ganjun C (2020) .Int J Mol Sci 21:2877.

   , ,

10. Yujuan G, Tian L, Dan Y (2022) .Front Endocrinol (Lausanne) 13:868720.

    , ,